How will the General Proximity and Daiichi Sankyo partnership benefit cancer patients?

The partnership will focus on discovering and advancing induced proximity medicines, which facilitate accurate and selective alteration of proteins responsible for disease, thereby opening up therapeutic possibilities for targets that have been challenging to tackle using traditional methods.

Home / Health / Daiichi Sankyo and General Proximity Forge Oncology Partnership to Advance Induced Proximity Medicines

Daiichi Sankyo and General Proximity Forge Oncology Partnership to Advance Induced Proximity Medicines

Q: What is the OmniTAC discovery platform?

The OmniTAC discovery platform enables unbiased screening of effector proteins that can modulate disease-relevant targets, offering a distinct pathway for drug discovery.

14 Nov

•

Summary

General Proximity and Daiichi Sankyo collaborate on induced proximity medicines for cancer
OmniTAC discovery platform to identify new effector-target pairs for first-in-class therapies
Daiichi Sankyo is a leader in oncology research and development

Daiichi Sankyo and General Proximity Forge Oncology Partnership to Advance Induced Proximity Medicines

On November 14, 2025, General Proximity announced a multi-target partnership with Daiichi Sankyo to apply the OmniTAC discovery platform to oncology programmes. The collaboration will focus on discovering and advancing induced proximity medicines for cancer treatment.

These innovative medicines facilitate accurate and selective alteration of disease-causing proteins, opening up therapeutic possibilities for targets that have been difficult to address using traditional methods. General Proximity's OmniTAC platform enables unbiased screening of effector proteins that can modulate disease-relevant targets, offering a distinct pathway for drug discovery.

Daiichi Sankyo, a leader in oncology research and development, entered the collaboration through its Research Institute located in Boston, Massachusetts. General Proximity founder and CEO Armand Cognetta expressed excitement to work with such a strong collaborator, stating that the agreement represents an important validation of their novel induced proximity approach and the potential of the OmniTAC platform to deliver innovative solutions for patients.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.